Drug Patent Formulation Intelligence: The Definitive Guide to Decoding Competitor Strategy
Why Formulation Patents Are the Most Undervalued Asset in Pharma IP The pharmaceutical industry spent roughly $260 billion on R&D […]
Biosimilar Patent Strategy: The Complete IP, Litigation, and Market Entry Playbook
For biopharma IP teams, portfolio managers, R&D leads, and institutional investors who track biologic patent cliffs for a living. 1.
Biosimilar Patent Strategy: The Complete IP, Litigation, and Market Entry Playbook Read Post »
How Academic Researchers and Policy Experts Use DrugPatentWatch
Books and Research Papers Citing DrugPatentWatch All Years | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 2025 — 11 Books and Research Papers Citing DrugPatentWatch Gregory, A. (2025).
How Academic Researchers and Policy Experts Use DrugPatentWatch Read Post »
The Patent Playbook Your Lawyers Won’t Write: The Complete Framework for Protecting Drug Revenue
A playbook for IP teams, portfolio managers, and R&D leads — from Paragraph IV mechanics and biosimilar patent dance tactics
Fix the Formula to Win the Generic Race: Overcoming Formulation Challenges in Generic Drug Development
The business of generic drug development is often misunderstood as a simple exercise in duplication. For many years, we operated
CDMO Price Benchmarking: Unlocking Market Domination Through Strategic Manufacturing Partnerships
How commercial manufacturing costs actually get built, what drives them, how CDMOs protect their pricing through IP assets, and what
Who Owns the AI-Discovered Drug? The Patent Ownership Guide Pharma IP Teams Need Now
The patent system did not anticipate generative chemistry. When Congress codified the requirement that inventors be ‘natural persons’ in 35
Who Owns the AI-Discovered Drug? The Patent Ownership Guide Pharma IP Teams Need Now Read Post »
MRAs That Actually Work: The Regulatory Fast-Track Every Generic Drug Team Needs to Map Now
A deep-dive reference for pharma IP teams, portfolio managers, regulatory strategists, and institutional investors tracking generic market entry timelines.
Specialty Generics: The $167B IP Playbook Pharma Analysts Need Now
1. What Are Specialty Generics — and Why the Definition Matters Defining the Asset Class With Precision The term ‘specialty
Specialty Generics: The $167B IP Playbook Pharma Analysts Need Now Read Post »
